Biogen to Acquire Apellis for $5.6 B, Shares Jump 136% on Deal

Why It Matters

The Biogen‑Apellis transaction marks one of the largest biotech M&A deals of the year, signaling a decisive shift toward complement‑system therapeutics—a class still in its early commercial phase but with high unmet‑need potential. By securing two FDA‑approved drugs and a pipeline that targets rare kidney diseases, Biogen diversifies away from its legacy neuroscience focus, aiming to stabilize earnings amid a slowing market for multiple‑sclerosis and Alzheimer’s treatments. The deal also illustrates how cash‑rich incumbents are using acquisitions to accelerate entry into niche therapeutic areas where organic development timelines are long and regulatory risk is high. For the broader industry, the deal underscores the premium investors are willing to pay for proven commercial assets in rare diseases, especially when paired with a pipeline that promises next‑generation indications. The CVR component reflects a growing trend of performance‑based earn‑outs that align seller incentives with post‑deal growth, potentially setting a template for future biotech consolidations.

Key Takeaways

• Biogen to acquire Apellis for $41 per share, total cash consideration ~ $5.6 billion
• Apellis shares surged 135.7% to $40.28, volume >40 million shares on announcement
• EMPAVELI and SYFOVRE generated $689 million combined net sales in 2025
• Deal includes a CVR offering up to $4 per share contingent on SYFOVRE sales targets
• Integration aims to accelerate felzartamab Phase 3 readout slated for H1 2027

Pulse Analysis

Biogen’s acquisition of Apellis is a textbook example of a legacy biotech using cash reserves to pivot into high‑growth, high‑margin rare‑disease segments. The company’s neuroscience franchise has faced pricing pressure and mixed clinical outcomes, prompting CEO Chris Viehbacher to pursue a "transformation" strategy centered on immunology. By locking in two best‑in‑class complement inhibitors, Biogen not only adds immediate revenue but also gains a platform that could be leveraged across multiple renal and ophthalmic indications, creating cross‑selling opportunities that are rare in the fragmented biotech landscape.

From a valuation perspective, the $5.6 billion price tag translates to roughly 8.1× 2025 combined sales of EMPAVELI and SYFOVRE, a multiple that aligns with recent premium deals for rare‑disease assets. The CVR structure mitigates some acquisition risk, tying a portion of the purchase price to future performance—a clever way to appease shareholders while preserving cash flow for integration. However, the deal also raises integration risk: aligning Apellis’s U.S. sales force with Biogen’s existing infrastructure, preserving talent, and ensuring regulatory compliance for felzartamab will be critical.

Looking ahead, the success of the acquisition will hinge on Biogen’s ability to sustain SYFOVRE’s market share in geographic atrophy, a space where competition from anti‑VEGF therapies is intensifying. Moreover, the anticipated Phase 3 data for felzartamab could unlock a multi‑billion‑dollar opportunity in nephrology, a market where few biologics have achieved dominance. If Biogen can deliver on these fronts, the deal could serve as a catalyst for a broader wave of immunology‑focused M&A, reshaping the competitive dynamics of the biotech sector for years to come.